Dronabinol
Product Images NDC 0527-4125

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Dronabinol (NDC 0527-4125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lannett Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2.5 mg (2.5 mg 60s)

Label for Dronabinol Capsules, USP 2.5 mg by Lannett Company, Inc. The label includes the NDC 0527-4125-35 and indicates a package size of 60 capsules for prescription use. Storage and handling instructions are noted, along with distributor and manufacturer details.*

FDA Label Image

Abs (Dronabinol Absorption)

Data table summarizing multiple-dose pharmacokinetic parameters of Dronabinol in healthy subjects under fasted conditions, including mean and standard deviation of maximum plasma concentration (Cmax), median time to maximum concentration (Tmax), and area under the plasma concentration-time curve (AUC) for 2.5 mg, 5 mg, and 10 mg twice daily doses.*

FDA Label Image

Fig1 (Dronabinol Figure1)

A line graph titled 'Mean Appetite Change from Baseline' showing mean appetite changes over 6 weeks. The graph compares two groups: Dronabinol 2.5 mg BID (filled circles) and Placebo (open circles). The vertical axis measures appetite change in mm on a visual analog scale (VAS) from 0 to 25, while the horizontal axis represents time in weeks. Dronabinol shows a greater increase in appetite over time, with statistically significant differences marked by asterisks at weeks 4 and 6 (p-value < 0.05).*

FDA Label Image

Rc (Dronabinol Rc)

A textual list outlining side effects associated with the drug Dronabinol by Lannett Company, Inc. The side effects include dizziness, euphoria, paranoia, sleepiness, abnormal thoughts, abdominal pain, nausea, and vomiting.*

FDA Label Image

Struct (Dronabinol Struct)

Chemical structure diagram of dronabinol, showing its molecular framework with labeled carbon, hydrogen, and oxygen atoms forming a complex ring and hydrocarbon structure.*

FDA Label Image

Adr (Dronabinol Adv)

A table listing common and less common adverse reactions reported in clinical trials for DRONABINOL, organized by system organ class. It categorizes reactions by incidence greater than 1% and less than or equal to 1%, detailing symptoms such as asthenia, palpitations, dizziness, nausea, chills, hypotension, diarrhea, myalgias, depression, cough, skin flushing, and vision difficulties.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.